Your Body Carries Two to Four Times More Cholesterol Than It Needs

Million Dollar Molecule – Part 2

What mass-balance modeling shows about the gap between physiological requirement and modern population averages — and why the surplus still matters, even when it isn’t harming any specific tissue.

The average American adult carries about 5.6 grams of cholesterol circulating in plasma at any given moment — roughly the weight of a U.S. nickel. Careful mass-balance modeling of what lipoprotein particles need for structural integrity, plus what specialized tissues actually draw from the bloodstream each day, suggests the body’s true circulating requirement is closer to 1.5 to 2.7 grams. The two- to four-fold surplus isn’t toxic in itself. But it isn’t doing nothing, either — and understanding what it is and isn’t doing turns out to clarify a great deal of cardiovascular medicine.

120–150 g Total body cholesterol in a typical adult

2–5% Of that total, found in the plasma compartment

23% Of body cholesterol locked inside the brain

The two questions people conflate

Almost all confusion about cholesterol, both in clinical settings and in popular educational sources, comes from blurring two separate questions.

The first is straightforward: Does my body need cholesterol? The answer is yes, emphatically. Every cell membrane in the body contains it. Steroid hormones — cortisol, aldosterone, testosterone, estradiol — are derived from it. Bile acids, vitamin D, and synaptic function all depend on it. Without cholesterol, eukaryotic life as we know it does not exist.

The second question is different: Does the cholesterol concentration on a lipid panel reflect what my body needs? The lipid panel measures cholesterol concentration in plasma, the liquid fraction of blood, where it travels in lipoprotein particles. That is a transport-system measurement, not a whole-body inventory. Once the two questions are separated, much of the apparent paradox in modern cardiology — including how human beings can live healthy lives with LDL cholesterol below 30 mg/dL — comes apart neatly.

Where the cholesterol actually is

A 70-kilogram adult contains roughly 120 to 150 grams of total cholesterol, distributed across every tissue in the body.^1,2 The plasma compartment holds only 3 to 7 grams of that, depending on the measured total cholesterol concentration and the person’s plasma volume — between 2 and 5 percent of body cholesterol, not the 10 to 30 percent figure often repeated in educational sources, which conflates the rapidly-exchanging hepatic–plasma–erythrocyte pool with the whole body.

Where does the rest live? Mostly in cell membranes, where cholesterol is essential structural material. Skeletal muscle holds about 25–30 grams. Connective tissue and adipose hold another 25–32 grams. Skin holds 12–18 grams. The liver carries 4–6 grams as working stock for bile-acid production and lipoprotein assembly. The remaining tissues — heart, kidneys, lung, intestine, spleen, adrenals — each carry less than a gram individually but contribute meaningfully in aggregate.

And then there is the brain.

The brain is on its own

The single most cholesterol-rich organ in the body is the brain, which contains roughly 30 to 35 grams — about a quarter of total body cholesterol — packed into a tissue that makes up only about 2 percent of body weight.^3,4

The blood–brain barrier is impermeable to lipoprotein cholesterol. None of the cholesterol your liver makes, none of what you eat, none of what circulates in your plasma — none of it crosses into the brain.

Brain cells synthesize their own. Astrocytes produce most of it and shuttle it to neurons through a brain-specific lipoprotein system centered on apolipoprotein E. The pool turns over slowly: six months to five years for neuronal cholesterol, and on the order of decades for the cholesterol packed into myelin sheaths. The only meaningful exit route from the CNS is enzymatic conversion into a derivative called 24S-hydroxycholesterol, which can cross the blood–brain barrier and is cleared in plasma.⁴

This has practical implications. Statins, PCSK9 inhibitors, and other plasma-cholesterol-lowering therapies do not directly lower brain cholesterol. Concerns sometimes raised that lipid-lowering treatment might cause cognitive harm by depleting brain cholesterol stores rest on a misunderstanding of the anatomy: the brain’s cholesterol pool is metabolically isolated from the circulation, full stop.

Every cell makes its own

The brain isn’t unusual in synthesizing cholesterol locally. Every nucleated cell in the human body can synthesize cholesterol from acetyl-CoA, via the roughly thirty-step mevalonate pathway.⁵ Skeletal muscle does most of its own. Skin makes around 90 percent of what it needs. Kidney, lung, and intestine all run the pathway competently.

The biosynthesis is biologically expensive. Producing a single cholesterol molecule requires eleven molecules of oxygen and roughly 100 ATP equivalents, and the pathway proceeds through several toxic intermediates that must be carefully managed.⁶ The fact that nearly every cell has evolved and retained this elaborate machinery is itself informative: local cholesterol supply isn’t optional, and tissues did not evolve to rely on the bloodstream to meet their needs.

Whole-body synthesis runs at about 10 milligrams per kilogram per day — roughly 700 mg in a 70-kilogram adult.⁵ The liver, often described as the site of cholesterol synthesis, contributes only about 10 percent of total body synthesis in humans. The remaining 90 percent is extrahepatic. Your tissues are mostly making their own.

So what is the blood transport system actually for?

If every tissue can synthesize its own cholesterol, the obvious next question is what the circulating lipoprotein system is doing. Three things, mainly.

01  Triglyceride distribution. Very-low-density lipoprotein (VLDL) particles secreted by the liver carry triglycerides to peripheral tissue for energy or storage. LDL is what’s left of VLDL after lipoprotein lipase has stripped off the triglycerides — a kinetic byproduct of energy delivery, not a purpose-built cholesterol courier. This reframing matters: LDL didn’t evolve to deliver cholesterol; it emerged from a system whose primary job is moving fat.

02  A kinetic chemical-potential buffer. Free cholesterol on every lipoprotein surface is in continuous spontaneous equilibrium with the cell membranes it encounters. This system maintains a near-uniform thermodynamic activity of cholesterol across all extracellular lipid surfaces, smoothing out moment-to-moment variation in any one tissue’s local supply.⁷

03  Delivery to a small set of tissues whose demand exceeds local synthesis. These are mainly the adrenal cortex (cortisol and aldosterone), the gonads (sex steroids), and, during pregnancy, the placenta. For a nonpregnant adult at baseline, the net obligate uptake of cholesterol from plasma is approximately 50 milligrams per day — small relative to whole-body synthesis.

None of these three functions require carrying around 5–7 grams of plasma cholesterol. The structural-buffer function requires enough particles for the system to remain stable. The delivery function requires the kinetic floor of about 50 mg per day. Both can be met at plasma cholesterol concentrations far below what most modern adults exhibit.

How much circulating cholesterol does the body actually require?

This is the question the prior sections have been setting up. Two functional requirements need to be satisfied for the circulating system to work.

The first is structural integrity. Every circulating lipoprotein particle — LDL, HDL, VLDL — needs free cholesterol on its surface to hold the phospholipid monolayer together. A representative 22-nanometer LDL particle carries about 400 free cholesterol molecules on its surface; an HDL carries about ten.⁸ Summed across all circulating particle classes at typical particle counts, this comes to roughly 25 to 30 mg/dL of structural surface free cholesterol.

The second is delivery to high-demand tissues, which, as noted, is on the order of 50 mg per day for a nonpregnant adult.

Building a transparent transport model — counting particles, free cholesterol per particle, core cholesteryl-ester cargo, and a reasonable reserve for tissue demand — and running it across the plausible parameter range, the model-estimated minimum plasma total cholesterol for a nonpregnant adult under baseline conditions comes out at roughly:

50 to 90 mg/dL total cholesterol — sensitivity range 40 to 110 — sufficient to maintain a functional lipoprotein transport system and deliver what the body’s high-demand tissues actually need.

In plasma cholesterol mass: roughly 1.5 to 2.7 grams at a representative plasma volume of three liters. This is the modeled floor. It is a calculation, not a measurement — but as the next section shows, the model’s prediction is corroborated by what we observe in living humans.

Real humans live at the model’s floor

The transport model’s predicted floor isn’t theoretical. It matches the plasma cholesterol levels observed in two well-studied human populations.

PCSK9 loss-of-function carriers

PCSK9 is a hepatic protein that regulates how many LDL receptors hepatocytes display on their surface. People who carry two non-functional copies of the PCSK9 gene have abundant LDL receptors and clear plasma LDL aggressively. The originally-described African-American homozygotes from the Dallas Heart Study have lifelong plasma LDL cholesterol in the 14 to 29 mg/dL range — total cholesterol typically 50 to 80 mg/dL — with no observed abnormalities of cognition, fertility, steroidogenesis, or general health in the published cases.⁹ The number of reported homozygotes is small, so this is a constraint on the high side of the model’s floor rather than a definitive answer; but it is striking that the empirical observation lands squarely inside the model-predicted range.

PCSK9-inhibitor trial participants

Monoclonal antibodies against PCSK9 — evolocumab and alirocumab — pharmacologically reproduce the PCSK9 loss-of-function phenotype. The FOURIER trial randomized 27,564 patients with established cardiovascular disease, followed them for a median of 2.2 years on evolocumab, and achieved median on-treatment LDL cholesterol of about 30 mg/dL.¹⁰ Its open-label extension, FOURIER-OLE, followed 6,635 of those patients for an additional median of five years — bringing maximum cumulative exposure to about 8.4 years — without identifying any signal of adrenal insufficiency, hypogonadism, cognitive decline, hemorrhagic stroke, or muscle disease.¹¹ ODYSSEY OUTCOMES, with alirocumab in roughly 19,000 patients, showed the same.

These are large, prospective, well-monitored safety datasets. They don’t measure tissue saturation thresholds directly, but they bound the empirically demonstrated safe range of plasma LDL cholesterol from above: humans tolerate prolonged plasma LDL cholesterol in the 15 to 30 mg/dL range without identified clinical consequence. The transport model predicts this, and the human data confirms it.

So why does the excess matter?

Here is where it would be tempting to draw the wrong conclusion. The model says the body’s circulating requirement is about 50 to 90 mg/dL total cholesterol. The current US adult mean is 188 mg/dL (NHANES 2017–2018).¹² The excess is roughly two- to four-fold. Is the excess harmless?

No. And the reason is subtle but important.

The question of cholesterol as physiological need is separate from the question of cholesterol as cardiovascular risk. They are physiologically orthogonal. Excess plasma cholesterol does not poison any tissue, cause cells to malfunction, or cause organs to fail. But every additional apolipoprotein-B-containing particle in the bloodstream has a small probability per unit time of entering the arterial wall, becoming retained, becoming oxidized, and seeding an atherosclerotic plaque.¹³

The risk is cumulative across time. Mendelian randomization studies — which use genetic variants as natural experiments to test causality — show a log-linear relationship between cumulative apoB exposure and lifetime risk of atherosclerotic cardiovascular disease, extending below plasma LDL cholesterol of 20 mg/dL.^13,14 The slope of that line is approximately constant. There is no inflection where risk vanishes. There is no threshold below which exposure stops counting.

So the modern surplus is metabolically tolerated in the sense that no tissue is harmed by it. It is not tolerated in the sense of contributing nothing to long-term risk — it contributes proportionally to particle exposure, regardless of where on the dose-response curve you sit. The atherogenic question isn’t whether you need the cholesterol; it’s how many apoB particles are exposed to your arterial wall over your lifetime, and for how long.

Three claims worth taking away

First, the cholesterol circulating in your blood is a small and unrepresentative slice of total body cholesterol. The brain — the most cholesterol-rich organ — is sealed off from plasma. Most other tissues make their own.

Second, the circulating cholesterol actually required to sustain a working lipoprotein transport system and meet the demands of high-uptake tissues is roughly 50 to 90 mg/dL total cholesterol for a nonpregnant adult at baseline. Modern population averages exceed this by two- to four-fold. The surplus is metabolically tolerated.

Third, “metabolically tolerated” is not the same as “biologically neutral.” The cumulative atherogenic risk of carrying that surplus is real and causally established, even when no particular tissue is being damaged in the short term.

Your body needs cholesterol. Your blood mostly doesn’t need to carry as much of it as it does.

If those three claims feel paradoxical when stated together, that is because most of us were taught about cholesterol as if it were one thing. It isn’t. It is at least three different things — a whole-body structural pool, a circulating transport system, and a per-particle atherogenic exposure — and most clinical confusion comes from collapsing the distinctions.

The cleaner framing is the one in the pull quote above. Both halves are true. Holding them together is what modern preventive cardiology asks of us.

This piece distills a longer technical analysis, including a formal mass-balance model with explicit equations and a sensitivity analysis. For the full quantitative treatment — including the assumptions, parameter ranges, and worked unit-conversion arithmetic underlying the transport-floor estimate — see the accompanying manuscript. The author has no financial relationships with manufacturers of lipid-lowering therapies.

References

1. M. T. Mc Auley, D. J. Wilkinson, J. J. L. Jones, and T. B. L. Kirkwood. A whole-body mathematical model of cholesterol metabolism and its age-associated dysregulation. BMC Systems Biology, 6:130, 2012.
2. I. A. Pikuleva and C. Curcio. Cholesterol in the retina: the best is yet to come. Progress in Retinal and Eye Research, 41:64–89, 2014.
3. I. Björkhem and S. Meaney. Brain cholesterol: long secret life behind a barrier. Arteriosclerosis, Thrombosis, and Vascular Biology, 24:806–815, 2004.
4. J. M. Dietschy and S. D. Turley. Cholesterol metabolism in the central nervous system during early development and in the mature animal. Journal of Lipid Research, 45(8):1375–1397, 2004.
5. J. M. Dietschy, S. D. Turley, and D. K. Spady. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. Journal of Lipid Research, 34:1637–1659, 1993.
6. R. E. Summons, A. S. Bradley, L. L. Jahnke, and J. R. Waldbauer. Steroids, triterpenoids and molecular oxygen. Philosophical Transactions of the Royal Society B, 361:951–968, 2006.
7. Y. Lange and T. L. Steck. Cholesterol homeostasis and the escape tendency (activity) of plasma membrane cholesterol. Progress in Lipid Research, 47:319–332, 2008.
8. T. Hevonoja, M. O. Pentikäinen, M. T. Hyvönen, P. T. Kovanen, and M. Ala-Korpela. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochimica et Biophysica Acta, 1488:189–210, 2000.
9. J. C. Cohen, E. Boerwinkle, T. H. Mosley Jr., and H. H. Hobbs. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New England Journal of Medicine, 354(12):1264–1272, 2006.
10. M. S. Sabatine et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine, 376:1713–1722, 2017.
11. R. P. Giugliano et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease (FOURIER-OLE). Circulation, 146:1109–1119, 2022.
12. Y. Jin et al. US trends in cholesterol screening, lipid levels, and lipid-lowering medication use in US adults, 1999 to 2018. Journal of the American Heart Association, 12:e028205, 2023.
13. B. A. Ference et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38:2459–2472, 2017.
14. A. D. Sniderman et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiology, 4:1287–1295, 2019.

---

DEEP DIVE

Cholesterol Structure, Transport, and Biological Requirement

A mechanistic analysis of compartment partitioning, lipoprotein structural requirements, and the model-estimated minimum for the circulating transport system

Abstract

Background. Whole-body cholesterol distribution, lipoprotein structural requirements, and tissue dependence on circulating cholesterol are frequently conflated in clinical and educational sources, leading to overstatements of how much circulating cholesterol the body “requires.”

Methods. This analysis (i) defines a strict compartment-based vocabulary distinguishing total body cholesterol, tissue cholesterol, intracellular cholesterol, and circulating (plasma/serum) cholesterol, and (ii) builds a transparent transport-model estimate for the minimum circulating cholesterol concentration required to maintain lipoprotein structural integrity and to meet exogenous tissue demand, with stated assumptions, explicit unit-converted parameters, and sensitivity bounds. Equations and parameter ranges are given in the Methods appendix (Section 11).

Findings. (1) Total body cholesterol in an adult is approximately 120–150 g; the rapidly-exchanging plasma pool of 3–7 g (depending on plasma volume and measured total cholesterol concentration) represents 2–5% of body content. (2) The brain alone contains ~30–35 g, isolated from plasma by the blood–brain barrier. (3) Plasma cholesterol is ~70% esterified / ~30% free. (4) A representative 22-nm modeled LDL particle (Hevonoja reconstruction) contains ~2,200 cholesterol molecules, ~18% of which is surface free cholesterol; LDL is heterogeneous and these numbers should not be applied uncritically to all LDL particles. (5) Under stated transport-model assumptions and using NMR-consistent particle counts (LDL-P in nmol/L → ~10¹⁶–10¹⁷ particles/dL; HDL-P in µmol/L → ~10¹⁸ particles/dL), the model-estimated minimum plasma total cholesterol that simultaneously stabilizes the lipoprotein system and supplies ~50 mg/day of net exogenous demand in a nonpregnant adult is approximately 50–90 mg/dL (sensitivity 40–110 mg/dL). This is a calculated scenario, not a demonstrated physiological minimum.

Conclusions. Modern US adult mean plasma total cholesterol of ~188 mg/dL (NHANES 2017–2018) exceeds the model-estimated transport floor by a factor that is assumption-sensitive but consistently > 2. The surplus is metabolically tolerated, causally tied to ASCVD risk on a per-apoB-particle basis, and not required for any known physiological function. Clinical guidelines that recommend LDL-C reduction for ASCVD prevention operate in a different epistemic register (event reduction in trials) than this paper (mass-balance modeling); the two are complementary, not in conflict.

1. Compartment-Based Vocabulary

Every cholesterol claim in this paper specifies (i) the compartment, (ii) the chemical form, and (iii) the units. Conflating clinical lipid-panel concentrations with tissue or whole-body cholesterol mass is the source of most quantitative errors in the lay and educational literature. The following terminology is used throughout. [1]

Term	Meaning	Typical units
Plasma TC / serum TC	Total cholesterol concentration in the corresponding blood fraction (calculated or directly measured on a routine lipid panel)	mg/dL or mmol/L
Plasma LDL-C / HDL-C / VLDL-C	Cholesterol carried by the named lipoprotein class in plasma	mg/dL or mmol/L
LDL-P / HDL-P	Number concentration of LDL or HDL particles (typically measured by NMR spectroscopy)	LDL-P in nmol/L; HDL-P in µmol/L (note different orders of magnitude)
Plasma free cholesterol / plasma cholesteryl ester	Chemical partition of plasma cholesterol between unesterified and esterified forms (typically ~30% / ~70%)	mg/dL, mmol/L, or % of plasma TC
Plasma cholesterol mass	Plasma TC × plasma volume; the absolute cholesterol mass circulating in plasma at one moment	g (= mg/dL × dL_plasma / 1000)
Circulating cholesterol mass	Plasma cholesterol mass + cholesterol carried in erythrocyte membranes (rapidly exchanges with plasma)	g
Tissue cholesterol concentration	Cholesterol per unit mass of tissue (e.g., brain at ~23 mg/g wet weight)	mg/g wet or dry weight
Cellular / subcellular cholesterol	Cholesterol in a specific cell type, organelle membrane, or pool	mol% of membrane lipids; µg/mg protein
Total body cholesterol	Whole-body cholesterol mass across all tissues and fluids	g
Model-estimated transport floor	Calculated minimum plasma cholesterol concentration that satisfies the structural and delivery functions of the circulating lipoprotein system under stated assumptions	mg/dL

 

■ Lipoprotein particle units are NMR conventions NMR lipoprotein subfraction analysis (LipoProfile and similar) reports LDL-P in nanomolar (nmol/L), reflecting the ~10¹⁵–10¹⁸ particles/L range typical for adults. HDL-P is conventionally reported in micromolar (µmol/L) because HDL is more abundant on a per-particle basis. This paper uses the NMR conventions throughout and converts to particles per dL with explicit arithmetic.

 

■ Plasma vs serum Routine clinical lipid panels are performed on either serum or plasma; the difference in measured cholesterol is small (typically < 3%). Unless specified, all circulating cholesterol concentrations refer to plasma or serum interchangeably.

2. Systemic Distribution and Mass Balance

2.1 Total body cholesterol

Total body cholesterol in an adult is approximately 120–150 g, with body-weight scaling. The range reflects between-subject and between-method variability in tissue-distribution studies. [2][3] Older textbook citations of ~35 g represent only Goodman’s rapidly-exchanging Pool A (liver + plasma + erythrocytes + part of viscera) in the kinetic tracer model, not whole-body content. Direct quantitative tissue analysis (Sabine, 1977, recapitulated in modern reviews) places adult human total body cholesterol at the higher figure, with brain, connective tissue including adipose, and skeletal muscle each contributing roughly 25–35 g. [2][3]

Goodman’s three-pool tracer model defines a rapidly-exchanging Pool A (liver, plasma, erythrocytes, splanchnic) of 15–30 g, a slowly-exchanging Pool B (skeletal muscle, adipose, dense connective tissue) of 35–60 g, and a kinetically isolated CNS pool of ~30–35 g. [4][5] The plasma compartment alone contains 3–7 g of cholesterol, depending on plasma volume and measured plasma total cholesterol concentration.

2.2 Tissue distribution

Distribution under the assumption of ~140 g total body cholesterol (representative midpoint). All entries are tissue cholesterol mass. [2][3]

Compartment	Cholesterol (g)	% of body total	Dominant chemical form
Brain / CNS (myelin + neural membranes)	30–35	~22–25%	>99.5% free (unesterified)
Skeletal muscle	~25–30	~18–22%	Free (plasma membrane)
Connective tissue, adipose, body fluids	~25–32	~18–23%	Mixed; CE accumulates with age in tendon/dura
Skin	~12–18	~9–13%	Free
Other viscera (lung, kidney, intestine, etc.)	~12–18	~9–13%	Free predominantly
Liver	~4–6	~3–4%	Mixed FC + CE
Plasma / circulating pool	3–7	~2–5%	~70% CE / ~30% FC
Heart, spleen, adrenals (per organ)	<1 each	<1%	High density per gram (adrenals ≥ 25 mg/g)

The CNS contains ~22–25% of body cholesterol at the highest tissue concentration (~23 mg/g wet weight). [5][6] The blood–brain barrier is impermeable to lipoprotein cholesterol; the entire CNS pool is synthesized locally. Cortical neuronal cholesterol turns over with a half-life of 6 months to 5 years; myelin cholesterol turns over on the order of decades. Net efflux from the CNS occurs primarily as 24S-hydroxycholesterol, which traverses the blood–brain barrier and is cleared in plasma. [5][6][7]

2.3 Plasma cholesterol mass at different plasma total cholesterol concentrations

Plasma cholesterol mass is the product of plasma volume and plasma total cholesterol concentration. At a representative plasma volume of 3.0 L:

Plasma TC (mg/dL)	Plasma cholesterol mass (g, 3.0 L plasma)	Clinical context
50	1.5	Below typical neonatal range; rare LOF mutations
80	2.4	Reported PCSK9 LOF homozygote range
100	3.0	PCSK9 inhibitor on-treatment targets
150	4.5	Therapeutic target on intensive lipid-lowering
188	5.6	US adult mean (NHANES 2017–2018) [8]
220	6.6	Borderline-elevated
280	8.4	Heterozygous FH range

 

■ Plasma volume varies with body size Plasma volume in adults is approximately 40–45 mL/kg body weight (~2.8–3.2 L for a 70-kg adult, ~3.5–4.0 L for a 90-kg adult). All plasma mass calculations in this paper use a representative 3.0 L unless otherwise stated.

2.4 Subcellular distribution and the ER cholesterol sensor

Within most non-neural cells, the plasma membrane holds 60–90% of cellular cholesterol at 30–40 mol% of PM lipids, while the endoplasmic reticulum maintains only 3–6 mol%. [9][10] The gradient is enforced by SREBP2 coupled to SCAP and Insig: when ER cholesterol exceeds ~5 mol%, SCAP retains SREBP2 in the ER and synthesis is suppressed. [11] Das et al. (eLife 2014) resolved PM cholesterol into three functional pools using a Perfringolysin O (PFO*) probe: a sphingomyelin-sequestered pool (~15 mol% of PM lipids), an “essential” pool required for cell viability, and an “accessible” pool that fluxes to the ER to regulate synthesis. [11][12] The accessible pool—not bulk PM cholesterol—is the regulatory signal.

▲ PFO* binding threshold applies to plasma-membrane bilayers, not lipoprotein monolayers. The 35 mol% PFO*-accessibility threshold in plasma membranes reflects bilayer architecture and sphingomyelin–cholesterol complexation specific to the PM. [11][12] LDL and HDL surfaces are phospholipid monolayers stabilized by apolipoproteins; they have different lipid composition, leaflet asymmetry, and packing constraints. The threshold should not be applied directly to lipoprotein surfaces without further analysis.

2.5 Daily turnover

Whole-body de novo cholesterol synthesis in adults is approximately 10 mg/kg/day (~700 mg/day in a 70-kg adult, ~880 mg/day in an 88-kg adult). The liver contributes only ~10% of total synthesis in humans; the majority is extrahepatic. [13] Three-pool tracer studies of plasma cholesterol turnover give a total production rate (synthesis plus dietary absorption) of ~1.0–1.2 g/day in normolipidemic subjects. [4] Dietary intake (~300–500 mg/day on a Western diet, ~30–50% absorbed) is compensated by down-regulation of endogenous synthesis. [14]

3. Lipoprotein Architecture and Cholesterol Partitioning

3.1 Representative 22-nm LDL particle composition

The reconstruction below is from Hevonoja et al. (BBA 2000) for a representative LDL particle of 22 nm diameter. [15][16][17]

Component	Molecules / particle	Mass fraction (%)	Location
Cholesteryl esters (CE)	~1,600	40–45%	Core
Unesterified cholesterol (FC)	~600	8–10%	~400 surface, ~200 core
Triglycerides (TG)	~170	5–9%	Core
Phosphatidylcholine	~450	} 19–21% combined	Surface monolayer
Sphingomyelin	~185	(phospholipid total)	Surface monolayer
ApoB-100 (single copy)	1	20–25%	Wraps the surface

Total cholesterol per representative LDL particle is ~2,200 molecules; surface FC accounts for ~18% of LDL cholesterol. Some general references cite ~1,500 cholesterol per average LDL particle, reflecting different averaging schemes across the LDL size distribution; both numbers are central-tendency descriptions of an inherently heterogeneous population. [16]

▲ LDL is heterogeneous. In-vivo LDL spans ~22–27.5 nm with substantial compositional variation; small dense LDL carries less cholesterol per particle and is enriched in TG, while large buoyant LDL carries more. The Hevonoja reconstruction is a representative central-tendency particle and should not be applied uncritically to all LDL species.

3.2 Plasma free-to-esterified ratio

Direct enzymatic and chromatographic measurement in healthy human serum shows plasma free cholesterol at ~25–30% of total plasma cholesterol, with the esterified fraction at ~70–75%. [18][19] An elevated FC/CE ratio is associated with LCAT dysfunction, familial chylomicronemia, and an independent atherogenic signal in some studies. [20]

3.3 Surface free cholesterol: structural role

Free cholesterol on the lipoprotein surface intercalates between phospholipid acyl chains, with its 3β-hydroxyl projecting into the aqueous interface and its rigid sterol ring aligned with the lipid tails. This “condensation” reduces free volume in the monolayer, decreases its permeability to water, and increases mechanical stability of the particle. [21][22] FC at ~25 mol% of surface lipids is compatible with a liquid-ordered, well-packed monolayer; this configuration supports particle stability and lateral mobility for enzymatic processing. [23]

3.4 Free cholesterol exchange

Free cholesterol on lipoprotein surfaces is in spontaneous equilibrium with cell membranes and other lipoprotein particles via passive aqueous diffusion. Exchange half-time scales inversely with surface curvature: ~5 min for nascent HDL, ~45 min for LDL. [21][23] This kinetic system maintains a near-uniform thermodynamic activity of cholesterol across all extracellular lipid surfaces. [22][23]

4. Cholesteryl Esters: Transport Cargo

Cholesteryl esters are fully hydrophobic and reside in the lipoprotein core as a liquid or liquid-crystalline droplet. CE in LDL represents 40–45% of particle mass and provides the bulk of cholesterol delivered to cells via receptor-mediated endocytosis, where lysosomal acid lipase liberates free cholesterol for use. [17]

CETP shuttles CE from HDL to apoB-containing lipoproteins in exchange for triglycerides, enriching apoB particles with cholesterol cargo. A substantial fraction of apoB-particle core CE therefore reflects cholesterol that has cycled through peripheral cells, plasma, and HDL before being transferred onto LDL, superimposed on hepatic cholesterol pools secreted as VLDL. [24]

5. HDL Maturation

Nascent HDL is secreted as lipid-poor apoA-I that acquires phospholipid and free cholesterol from peripheral cells via ABCA1, forming a discoidal particle of two apoA-I molecules in a “double-belt” conformation. [25] LCAT, activated by apoA-I, transfers an acyl group from the sn-2 position of phosphatidylcholine to surface FC, generating CE that migrates into the hydrophobic core. [23][25]

As CE accumulates, the discoidal bilayer becomes spherical. Mature HDL2 reaches ~10–12 nm diameter and carries ~30–60 cholesterol molecules per particle (mostly CE), with ~5–15 surface FC. [23] The CE either returns directly to the liver via SR-B1 or transfers to apoB particles via CETP for hepatic clearance through LDLR. [23][24]

6. Tissue Requirements: De Novo Synthesis and Exogenous Uptake

6.1 Most nucleated tissues can synthesize cholesterol de novo

Every nucleated cell in the human body expresses the complete mevalonate–cholesterol biosynthetic pathway. [13][26] Under usual conditions, most tissues are not absolutely dependent on continuous exogenous cholesterol supply from plasma; the quantitative balance between local synthesis and lipoprotein-derived uptake varies by tissue, age, and physiological state.

Tissue	Primary cholesterol source	Notes
Brain / CNS	Local synthesis (astrocytes → neurons via apoE)	BBB excludes lipoprotein cholesterol; net efflux via 24S-OH-cholesterol [7]
Skeletal muscle	Predominantly local synthesis	Low demand for new sterol
Skin	~90% local synthesis	Supports barrier function
Adrenal cortex	Mixed: LDLR > SR-B1 in humans; reverse in rodents [27][28]	Stored CE buffers acute steroidogenic demand
Gonads (testes, ovaries)	Mixed: LDLR + SR-B1; reproductive-state-dependent	Pregnancy and lactation raise demand
Placenta	Maternal LDL and HDL; pregnancy only	Outside scope of nonpregnant adult analysis
Liver	Synthesis + dietary + reverse transport	Master regulator; secretes VLDL

In human adrenocortical and gonadal physiology, LDLR-mediated endocytosis carries greater quantitative weight than SR-B1 for cholesterol delivery — opposite to the rodent pattern in which SR-B1 dominates. SR-B1 nonetheless remains expressed and biologically active in human steroidogenic tissues, and SR-B1 loss-of-function in humans produces subtle but real abnormalities in ACTH-stimulated cortisol response. The mixed-pathway nature of human steroidogenic cholesterol supply should be preserved in any mechanistic discussion. [27][28]

6.2 LDL-receptor kinetics: in-vitro and in-vivo are not interchangeable

In-vitro: in cultured human fibroblasts, high-affinity binding of LDL apoB-100 saturates at LDL protein concentrations below 50 µg/mL (Brown & Goldstein). [29][30] Catapano and colleagues (2024) describe this as a half-saturation corresponding to an LDL-C plasma equivalent of ~2.5 mg/dL, and combine it with the observation that interstitial-fluid LDL-C is ~20% of plasma LDL-C to argue that plasma LDL-C of ~12.5 mg/dL would saturate tissue LDLR. [31] This argument depends on intermediate assumptions about LDL protein-to-cholesterol mass ratio, interstitial-fluid composition, and uniformity of fibroblast LDLR behavior; this paper cites the argument without endorsing it as a measured human threshold.

In-vivo: organ-level LDL clearance in rat and hamster (Spady & Dietschy) gives Km ≈ 90 mg/dL — roughly 30-fold higher, reflecting unstirred boundary layers, capillary permeability, and receptor density rather than intrinsic affinity. [32] This rodent in-vivo number is not directly portable to human tissue-level cholesterol-delivery thresholds.

▲ Receptor saturation kinetics are not a clean human delivery threshold. The chain (in-vitro fibroblast Km → plasma-equivalent LDL-C → interstitial-fluid LDLR saturation in adrenal/gonadal cells) depends on assumptions that have not been independently validated in humans, and hepatocytes are exposed to sinusoidal blood rather than to ordinary interstitial fluid. The substantively defensible claim is empirical: humans with very low plasma LDL-C, by genetics or therapy, have not shown clinical signs of cholesterol-delivery insufficiency in the reported populations.

6.3 Empirical observations: very low LDL-C in humans

Carriers of homozygous PCSK9 loss-of-function mutations are a small reported sample. The originally described Dallas Heart Study African-American homozygotes had lifelong plasma LDL-C of 14–29 mg/dL (total cholesterol typically 50–80 mg/dL) without overt clinical abnormalities in the limited published descriptions. [33][34] The total reported global population of such homozygotes remains small, so this evidence supports the absence of large-effect harm but does not prove a universal physiological minimum.

Larger evidence comes from PCSK9-inhibitor randomized trials. FOURIER (n = 27,564) had a median randomized follow-up of 2.2 years, with on-treatment median LDL-C of 30 mg/dL and no signal of adrenal insufficiency, hypogonadism, cognitive decline, hemorrhagic stroke, or muscle disease. [35] ODYSSEY OUTCOMES (n = 18,924) had a median follow-up of 2.8 years with similar safety findings. [36] The FOURIER Open-Label Extension (FOURIER-OLE, n = 6,635 of the original 27,564) added a median 5.0 years of evolocumab exposure, bringing cumulative exposure in that subset to ~8.4 years, with no new safety signal. [37] These are large, prospective safety data; they are not a direct measurement of human cholesterol delivery thresholds but they bound the empirically demonstrated safe range of plasma LDL-C from above.

Interstitial-fluid LDL is reported at ~10–20% of plasma LDL concentration in human peripheral lymph studies. [38][39] These data are descriptive and do not establish a measured human tissue saturation threshold.

7. A Transport-Model Estimate of the Minimum Circulating Cholesterol

■ What this section is and is not. This section presents a transport-model estimate of the minimum plasma cholesterol concentration that simultaneously (i) sustains the structural integrity of the circulating lipoprotein system and (ii) supplies the net daily exogenous cholesterol demand of a nonpregnant adult under usual conditions. The estimate is calculation, not measurement. Equations and parameter values are in Section 11.

7.1 Structural integrity

All circulating lipoprotein particles require surface free cholesterol to stabilize their phospholipid monolayer. Using NMR-consistent particle counts (LDL-P in nmol/L; HDL-P in µmol/L) and explicit unit conversion: [15][17]

Particle class	Class concentration (clinical)	Particles per dL	Surface FC per particle	Surface FC contribution (mg/dL)
LDL	LDL-C 100 mg/dL; LDL-P ~1,200 nmol/L	~7.1 × 10¹⁶	~400	~18
HDL	HDL-C 50 mg/dL; HDL-P ~30 µmol/L	~1.8 × 10¹⁸	~10	~12
VLDL / IDL	TG-driven; particle counts ~10¹⁵–10¹⁶ /dL	—	~variable	~2–3
Total surface FC (model, baseline TC ~190)	—	—	—	~30–33
Total measured plasma FC (~28% of TC at TC 190)	—	—	—	~50–55 (includes core FC and other)

The model-derived surface FC of ~30–33 mg/dL at typical clinical lipid values, plus core FC of ~10–15 mg/dL (LDL has ~200 core FC per particle, HDL has a smaller core FC contribution), and a small chylomicron-remnant and Lp(a) contribution, sums to approximately 45–55 mg/dL plasma FC. This matches the directly measured plasma FC fraction of ~25–30% of total cholesterol at total cholesterol ~190 mg/dL. [18][19]

7.2 Net daily exogenous cholesterol delivery to peripheral tissues

Reverse cholesterol transport tracer studies in healthy adults (Turner et al., 2012) estimate whole-body tissue FC efflux at 3.79 ± 0.88 mg/kg/h, reported in the original paper as ≈8 g/day; this corresponds to ~6.4 g/day at 70 kg or ~8 g/day at 88 kg (the study’s mean approximate body weight). [40] This is bidirectional exchange flux, not net delivery demand. Estimated net obligate exogenous uptake by tissues whose local synthesis is insufficient under baseline conditions, in a nonpregnant adult, is approximately:

Tissue / function	Estimated daily cholesterol use	Source of supply
Adrenal steroidogenesis (baseline)	~30–60 mg/day	Mostly LDLR-mediated; SR-B1 contribution
Gonadal steroidogenesis (nonpregnant adult, baseline)	< 10 mg/day	Predominantly LDLR-mediated in humans
Bile acid synthesis	~400 mg/day	Hepatic pool; not a peripheral demand
Extrahepatic membrane turnover (all)	~600–700 mg/day	Met by local synthesis
Net obligate exogenous demand (nonpregnant adult, baseline)	Order of tens of mg/day (~50 mg/day central estimate)	Met at very low plasma LDL-C

 

▲ Nonpregnant adult, baseline only. Pregnancy roughly doubles maternal plasma cholesterol; placental demand is on a different order of magnitude and is not captured here. Acute illness, severe stress, and rapid tissue regeneration also raise demand.

7.3 Combined model-estimated transport floor

Model output across a range of plasma TC values:

Plasma TC scenario	LDL surface FC (mg/dL)	HDL surface FC (mg/dL)	Total plasma FC (mg/dL)	Notes
TC 188 (US mean)	~18	~12	~50–55	Baseline
TC 100 (PCSK9-Rx target)	~10	~10	~30	Adequate; well above any structural floor
TC 70 (PCSK9 LOF homozygote)	~4	~9	~17	At or near model floor; empirically tolerated
TC 50 (extreme genetic)	~2	~8	~13	Below any well-validated empirical case

 

Bottom line: the transport model predicts that a nonpregnant adult under baseline conditions can maintain a functional circulating lipoprotein system and meet ~50 mg/day of exogenous tissue demand at plasma total cholesterol on the order of 50–90 mg/dL (sensitivity range 40–110 mg/dL). The chemical form remains roughly 70% esterified and 30% unesterified across this range. The model-floor estimate is in numerical agreement with the plasma TC observed in PCSK9 LOF homozygotes (~50–80 mg/dL), providing independent corroboration from clinical and genetic observation. Modern US adult mean plasma TC of ~188 mg/dL [8] exceeds the model-estimated floor by approximately 2–4×, depending on which sensitivity scenario is used.

7.4 Sensitivity bounds

Assumption varied	Range tested	Effect on transport-floor estimate
Plasma volume	2.5–4.0 L	Inverse scaling; primary effect on absolute mass, secondary on mg/dL
LDL-P at given LDL-C	± 50% of representative	Affects FC component proportionally
Surface FC per LDL particle	300–500	± 15% on FC component
FC per HDL particle	5–15	± 25% on HDL FC component
Net peripheral demand	20–150 mg/day	Adds 5–30 mg/dL margin
Pregnancy / acute illness	—	Model not applicable; demand can rise 2–10×
Combined plausible range (nonpregnant adult, baseline)	—	~40–110 mg/dL plasma TC

8. ApoB Causality and ASCVD Risk

Whether peripheral tissues require circulating cholesterol is a separate question from whether circulating apoB-containing lipoproteins are causally atherogenic. Mendelian randomization across > 50 genetic instruments (LDLR, PCSK9, HMGCR, NPC1L1, APOB, ANGPTL3, LPL, CETP) has established that the lifetime risk of ASCVD tracks cumulative apoB-particle exposure rather than absolute LDL-C concentration alone, with a log-linear relationship between apoB and event risk extending below 20 mg/dL LDL-C. [41][42]

The atherogenic risk imposed by a given circulating cholesterol mass is determined by particle number (apoB count) and residence time, not by whether the cholesterol is required for tissue delivery. The two questions are physiologically orthogonal.

9. Evolutionary and Mechanistic Context

Cholesterol biosynthesis requires 11 molecules of O₂ and roughly 100 ATP equivalents per cholesterol molecule, and involves toxic intermediates. [43][44] This expense is consistent with cholesterol having emerged as eukaryotes adapted to a rising atmospheric oxygen tension; cholesterol both consumes O₂ during synthesis and reduces membrane O₂ permeability, partially functioning as an O₂ sink. [44]

Under the modeling perspective developed in Section 7, the lipoprotein transport system is best interpreted as (i) a vehicle for triglyceride distribution — LDL is a kinetic byproduct of VLDL catabolism — and (ii) a kinetic chemical-potential buffer that maintains uniform sterol activity across all extracellular lipid surfaces. [22][23] Under this interpretation, the modern population’s circulating cholesterol concentration is set primarily by hepatic clearance capacity (LDLR density, PCSK9 activity, IDOL activity) rather than by peripheral demand.

10. Conclusions

• Total body cholesterol in an adult is approximately 120–150 g; the plasma compartment of 3–7 g represents 2–5%, not 10–30%, of body content.
• The brain contains ~30–35 g (22–25% of body cholesterol), entirely synthesized locally and isolated from plasma by the blood–brain barrier.
• A representative 22-nm LDL particle contains ~2,200 cholesterol molecules (~1,600 CE + ~600 FC, of which ~400 FC are on the surface). LDL is heterogeneous; these numbers describe a representative reconstruction.
• Plasma cholesterol is ~70% esterified and ~30% free.
• In humans, LDLR-mediated endocytosis carries greater weight than SR-B1 for adrenal and gonadal cholesterol uptake, but SR-B1 remains biologically active.
• Using NMR-consistent lipoprotein particle counts (LDL-P in nmol/L, HDL-P in µmol/L), the model-estimated minimum plasma total cholesterol for a nonpregnant adult under baseline conditions is approximately 50–90 mg/dL (sensitivity 40–110 mg/dL). This is a calculated scenario, not a directly measured human physiological minimum.
• Net daily exogenous cholesterol delivery to peripheral tissues in a nonpregnant adult under baseline conditions is on the order of tens of mg/day, easily met at plasma LDL-C in the 15–30 mg/dL range observed in PCSK9 LOF carriers and in PCSK9-inhibitor trial subjects (FOURIER median 2.2 years, FOURIER-OLE subset median 5.0 additional years), in whom no signal of cholesterol-delivery insufficiency has been reported.
• US adult mean plasma total cholesterol of ~188 mg/dL (NHANES 2017–2018) exceeds the model-estimated transport floor by approximately 2–4×, depending on which sensitivity scenario is used. The surplus is metabolically tolerated, causally tied to ASCVD risk on a per-apoB basis, and not required for any known physiological function in a nonpregnant adult under baseline conditions.

11. Methods Appendix

11.1 Scope

This appendix specifies the equations, parameter values, and assumptions used in the transport-model estimate of Section 7.

11.2 Equations

Plasma cholesterol mass:

M_plasma = TC × V_plasma / 1000   (g)

where TC is in mg/dL and V_plasma is in dL.

Conversion from NMR particle concentration to particles per dL:

N_particles_per_dL = [class-P] × 10⁻⁹ × N_A / 10        (LDL: [LDL-P] in nmol/L)

N_particles_per_dL = [class-P] × 10⁻⁶ × N_A / 10        (HDL: [HDL-P] in µmol/L)

where N_A = 6.022 × 10²³ /mol. The /10 converts L to dL.

Worked example, LDL-P = 1,200 nmol/L:

1,200 × 10⁻⁹ × 6.022 × 10²³ / 10 = 7.23 × 10¹⁶ particles/dL

Worked example, HDL-P = 30 µmol/L:

30 × 10⁻⁶ × 6.022 × 10²³ / 10 = 1.81 × 10¹⁸ particles/dL

Surface FC contribution from one lipoprotein class:

[FC]_class (mg/dL) = N_particles_per_dL × n_FC,class × MW_chol × 1000 / N_A

Worked example, LDL at LDL-C 100 (N = 7.23 × 10¹⁶/dL), 400 surface FC per particle, MW_chol = 386.7 g/mol:

7.23 × 10¹⁶ × 400 × 386.7 × 1000 / 6.022 × 10²³ = ~18.2 mg/dL

Total model-estimated transport floor:

TC_floor ≈ Σ [FC]_class,surface + Σ [FC]_class,core + CE_core,structural + CE_delivery_reserve

11.3 Parameter values used

Parameter	Central value	Source / basis	Sensitivity range
Plasma volume	3.0 L (= 30 dL)	~42 mL/kg × 70 kg	2.5–4.0 L
LDL-P at LDL-C 100 mg/dL	~1,200 nmol/L (= 7.1 × 10¹⁶ /dL)	NMR LipoProfile data; MESA, JUPITER	600–1,800 nmol/L
HDL-P at HDL-C 50 mg/dL	~30 µmol/L (= 1.8 × 10¹⁸ /dL)	NMR data	20–40 µmol/L
Surface FC per LDL particle	400	Hevonoja 2000 reconstruction [15]	300–500
FC per HDL particle (total)	~10	HDL2/3 composition reviews; calculated from HDL-C / HDL-P at central values	5–15
Net daily peripheral exogenous demand (nonpregnant adult)	~50 mg/day	Composite of adrenal/gonadal/membrane estimates [26][27]	20–150 mg/day
MW cholesterol	386.7 g/mol	Fixed	n/a
Avogadro’s number	6.022 × 10²³ /mol	Fixed	n/a

11.4 Assumptions

The transport-floor calculation depends on assumptions made explicit here:

• The nonpregnant adult is at metabolic steady state under baseline conditions (no pregnancy, no acute illness, no rapid tissue regeneration).
• Plasma volume is taken as a single representative value rather than individualized.
• Particle counts scale approximately linearly with class cholesterol concentration over the modeled range; this approximation breaks down at extremes.
• Surface FC per LDL is taken from the Hevonoja reconstruction; surface composition varies somewhat with particle size and remodeling state.
• FC per HDL particle reflects mature spherical HDL2/3 composition; nascent discoidal HDL has different per-particle FC content.
• Net peripheral demand is taken as order of tens of mg/day; this aggregates tissue-level values that have wide uncertainty under different endocrine states.
• Lp(a), chylomicrons, and chylomicron remnants are not modeled separately; including them would shift the FC contribution upward by a small amount.
• The model is steady-state and ignores diurnal, postprandial, and seasonal variation.

11.5 What this appendix does not establish

This appendix does not establish a measured human physiological minimum for total cholesterol. It provides a transparent, reproducible transport-model estimate. Direct empirical evidence for the safety of very low plasma LDL-C in humans (PCSK9 LOF carriers; PCSK9-inhibitor trial participants) is presented separately in Section 6.3 and remains the strongest evidence that the model’s predicted low floor is physiologically plausible. The two evidence streams are independent: a transport model and a clinical/genetic observation. They are numerically consistent — both indicate that plasma total cholesterol can fall to ~50–80 mg/dL without identified clinical consequence in a nonpregnant adult — but neither alone is dispositive.

References

1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455
2. Pikuleva IA, Curcio CA. Cholesterol in the retina: the best is yet to come. Prog Retin Eye Res. 2014;41:64-89. doi:10.1016/j.preteyeres.2014.03.002
3. Mc Auley MT, Wilkinson DJ, Jones JJ, Kirkwood TB. A whole-body mathematical model of cholesterol metabolism and its age-associated dysregulation. BMC Syst Biol. 2012;6:130. Published 2012 Oct 10. doi:10.1186/1752-0509-6-130
4. Goodman DS, Noble RP, Dell RB. Three-pool model of the long-term turnover of plasma cholesterol in man. J Lipid Res. 1973;14(2):178-188.
5. Dietschy JM, Turley SD. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res. 2004;45(8):1375-1397. doi:10.1194/jlr.R400004-JLR200
6. Björkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol. 2004;24(5):806-815. doi:10.1161/01.ATV.0000120374.59826.1b
7. Lütjohann D, Breuer O, Ahlborg G, et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A. 1996;93(18):9799-9804. doi:10.1073/pnas.93.18.9799
8. Gao Y, Shah LM, Ding J, Martin SS. US Trends in Cholesterol Screening, Lipid Levels, and Lipid-Lowering Medication Use in US Adults, 1999 to 2018. J Am Heart Assoc. 2023;12(3):e028205. doi:10.1161/JAHA.122.028205
9. Canfrán-Duque A, Rotllan N, Zhang X, et al. Macrophage-Derived 25-Hydroxycholesterol Promotes Vascular Inflammation, Atherogenesis, and Lesion Remodeling. Circulation. 2023;147(5):388-408. doi:10.1161/CIRCULATIONAHA.122.059062
10. van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol. 2008;9(2):112-124. doi:10.1038/nrm2330
11. Das A, Brown MS, Anderson DD, Goldstein JL, Radhakrishnan A. Three pools of plasma membrane cholesterol and their relation to cholesterol homeostasis. Elife. 2014;3:e02882. Published 2014 Jun 11. doi:10.7554/eLife.02882
12. Schoop V, Martello A, Eden ER, Höglinger D. Cellular cholesterol and how to find it. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866(9):158989. doi:10.1016/j.bbalip.2021.158989
13. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993;34(10):1637-1659.
14. Jones PJ, Pappu AS, Hatcher L, Li ZC, Illingworth DR, Connor WE. Dietary cholesterol feeding suppresses human cholesterol synthesis measured by deuterium incorporation and urinary mevalonic acid levels. Arterioscler Thromb Vasc Biol. 1996;16(10):1222-1228. doi:10.1161/01.atv.16.10.1222
15. Hevonoja T, Pentikäinen MO, Hyvönen MT, Kovanen PT, Ala-Korpela M. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim Biophys Acta. 2000;1488(3):189-210. doi:10.1016/s1388-1981(00)00123-2
16. Kumar V, Butcher SJ, Öörni K, et al. Three-dimensional cryoEM reconstruction of native LDL particles to 16Å resolution at physiological body temperature. PLoS One. 2011;6(5):e18841. Published 2011 May 9. doi:10.1371/journal.pone.0018841
17. Feingold KR. Introduction to Lipids and Lipoproteins. In: Feingold KR, Adler RA, Ahmed SF, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; January 14, 2024.
18. Leonard PJ, Shaper AG, Jones KW. Relationship between free and total cholesterol values in human serum. Am J Clin Nutr. 1965;17(6):377-380. doi:10.1093/ajcn/17.6.377
19. Saier EL, Nordstrand E, Juves MW, Hartsock RJ. The ratio of free to esterified cholesterol in serum. A new discriminant in correlating lipid metabolism with disease state. Am J Clin Pathol. 1979;71(1):83-87. doi:10.1093/ajcp/71.1.83
20. Bagheri B, Alikhani A, Mokhtari H, Rasouli M. The Ratio of Unesterified/esterified Cholesterol is the Major Determinant of Atherogenicity of Lipoprotein Fractions. Med Arch. 2018;72(2):103-107. doi:10.5455/medarh.2018.72.103-107
21. Lange Y, Steck TL. Cholesterol homeostasis and the escape tendency (activity) of plasma membrane cholesterol. Prog Lipid Res. 2008;47(5):319-332. doi:10.1016/j.plipres.2008.03.001
22. Maxfield FR, Tabas I. Role of cholesterol and lipid organization in disease. Nature. 2005;438(7068):612-621. doi:10.1038/nature04399
23. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol. 2010;21(3):229-238. doi:10.1097/mol.0b013e328338472d
24. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23(2):160-167. doi:10.1161/01.atv.0000054658.91146.64
25. Shih AY, Sligar SG, Schulten K. Maturation of high-density lipoproteins. J R Soc Interface. 2009;6(39):863-871. doi:10.1098/rsif.2009.0173
26. Cerqueira NM, Oliveira EF, Gesto DS, et al. Cholesterol Biosynthesis: A Mechanistic Overview. Biochemistry. 2016;55(39):5483-5506. doi:10.1021/acs.biochem.6b00342
27. Azhar S, Reaven E. Scavenger receptor class BI and selective cholesteryl ester uptake: partners in the regulation of steroidogenesis. Mol Cell Endocrinol. 2002;195(1-2):1-26. doi:10.1016/s0303-7207(02)00222-8
28. Gomez-Sanchez CE, Gomez-Sanchez EP. Cholesterol Availability and Adrenal Steroidogenesis. Endocrinology. 2024;165(4):bqae032. doi:10.1210/endocr/bqae032
29. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34-47. doi:10.1126/science.3513311
30. Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci U S A. 1973;70(10):2804-2808. doi:10.1073/pnas.70.10.2804
31. Borghi C, Bragagni A. There are those who would like zero LDL cholesterol. Eur Heart J Suppl. 2024;26(Suppl 1):i19-i22. Published 2024 Apr 17. doi:10.1093/eurheartjsupp/suae012
32. Spady DK, Bilheimer DW, Dietschy JM. Rates of receptor-dependent and -independent low density lipoprotein uptake in the hamster. Proc Natl Acad Sci U S A. 1983;80(11):3499-3503. doi:10.1073/pnas.80.11.3499
33. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-1272. doi:10.1056/NEJMoa054013
34. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79(3):514-523. doi:10.1086/507488
35. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664
36. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107. doi:10.1056/NEJMoa1801174
37. O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulation. 2022;146(15):1109-1119. doi:10.1161/CIRCULATIONAHA.122.061620
38. Sloop CH, Dory L, Roheim PS. Interstitial fluid lipoproteins. J Lipid Res. 1987;28(3):225-237.
39. Reichl D, Simons LA, Myant NB, Pflug JJ, Mills GL. The lipids and lipoproteins of human peripheral lymph, with observations on the transport of cholesterol from plasma and tissues into lymph. Clin Sci Mol Med. 1973;45(3):313-329. doi:10.1042/cs0450313
40. Turner S, Voogt J, Davidson M, et al. Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion. J Am Heart Assoc. 2012;1(4):e001826. doi:10.1161/JAHA.112.001826
41. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
42. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287-1295. doi:10.1001/jamacardio.2019.3780
43. Summons RE, Bradley AS, Jahnke LL, Waldbauer JR. Steroids, triterpenoids and molecular oxygen. Philos Trans R Soc Lond B Biol Sci. 2006;361(1470):951-968. doi:10.1098/rstb.2006.1837
44. Brown AJ, Galea AM. Cholesterol as an evolutionary response to living with oxygen. Evolution. 2010;64(7):2179-2183. doi:10.1111/j.1558-5646.2010.01011.x